Shanghai Yizhong Pharmaceutical Co Ltd Net Asset Quality Index
Shanghai Yizhong Pharmaceutical Co Ltd net asset quality index. Shanghai Yizhong Pharmaceutical Co Ltd (688091) has a Net Asset Quality Index of 94.6% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.54 Billion minus total liabilities of CN¥82.76 Million yields net assets of CN¥1.46 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Shanghai Yizhong Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
Net asset quality index of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. This chart shows how Shanghai Yizhong Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 8 annual periods from 2017 to 2024. As of September 2025, the index stands at 94.6%, representing net assets of CN¥1.46 Billion against total assets of CN¥1.54 Billion CNY. See 688091 total equity for net asset value and shareholders' equity analysis.
Shanghai Yizhong Pharmaceutical Co Ltd Net Asset Quality Index by Year (2017–2024)
Shanghai Yizhong Pharmaceutical Co Ltd net asset quality index by year from 2017 to 2024. The table below presents the year-by-year Net Asset Quality Index for Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024, covering 8 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Shanghai Yizhong Pharmaceutical Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 97.0% | CN¥1.41 Billion | CN¥1.45 Billion | CN¥42.97 Million | ▲ +3.9 pp |
| 2023 | 93.1% | CN¥1.46 Billion | CN¥1.57 Billion | CN¥108.52 Million | ▼ -4.3 pp |
| 2022 | 97.4% | CN¥1.32 Billion | CN¥1.35 Billion | CN¥35.42 Million | ▼ -0.5 pp |
| 2021 | 97.9% | CN¥1.18 Billion | CN¥1.20 Billion | CN¥25.02 Million | ▲ +3.8 pp |
| 2020 | 94.1% | CN¥243.51 Million | CN¥258.81 Million | CN¥15.30 Million | ▼ -1.5 pp |
| 2019 | 95.6% | CN¥265.35 Million | CN¥277.62 Million | CN¥12.26 Million | ▲ +3.1 pp |
| 2018 | 92.5% | CN¥212.18 Million | CN¥229.33 Million | CN¥17.15 Million | ▲ +0.1 pp |
| 2017 | 92.4% | CN¥197.57 Million | CN¥213.74 Million | CN¥16.17 Million | — |